LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

Tamoxifen resistance is a major problem in the treatment of ERa positive breast cancer. Here, the authors show that LEM4 confers tamoxifen resistance by activating the cyclin D-CDK4/6-Rb axis and ERa signaling in endocrine-resistant breast cancer.

Guardado en:

Detalles Bibliográficos
Autores principales:	Ang Gao, Tonghua Sun, Gui Ma, Jiangran Cao, Qingxia Hu, Ling Chen, Yanxin Wang, Qianying Wang, Jiafu Sun, Rui Wu, Qiao Wu, Jiaxi Zhou, Lin Liu, Junjie Hu, Jin-Tang Dong, Zhengmao Zhu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7ff9424b6d604decaed08aa4fac77058
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ff9424b6d604decaed08aa4fac77058
record_format	dspace
spelling	oai:doaj.org-article:7ff9424b6d604decaed08aa4fac770582021-12-02T14:38:49ZLEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway10.1038/s41467-018-06309-82041-1723https://doaj.org/article/7ff9424b6d604decaed08aa4fac770582018-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-06309-8https://doaj.org/toc/2041-1723Tamoxifen resistance is a major problem in the treatment of ERa positive breast cancer. Here, the authors show that LEM4 confers tamoxifen resistance by activating the cyclin D-CDK4/6-Rb axis and ERa signaling in endocrine-resistant breast cancer.Ang GaoTonghua SunGui MaJiangran CaoQingxia HuLing ChenYanxin WangQianying WangJiafu SunRui WuQiao WuJiaxi ZhouLin LiuJunjie HuJin-Tang DongZhengmao ZhuNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-17 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Ang Gao Tonghua Sun Gui Ma Jiangran Cao Qingxia Hu Ling Chen Yanxin Wang Qianying Wang Jiafu Sun Rui Wu Qiao Wu Jiaxi Zhou Lin Liu Junjie Hu Jin-Tang Dong Zhengmao Zhu LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
description	Tamoxifen resistance is a major problem in the treatment of ERa positive breast cancer. Here, the authors show that LEM4 confers tamoxifen resistance by activating the cyclin D-CDK4/6-Rb axis and ERa signaling in endocrine-resistant breast cancer.
format	article
author	Ang Gao Tonghua Sun Gui Ma Jiangran Cao Qingxia Hu Ling Chen Yanxin Wang Qianying Wang Jiafu Sun Rui Wu Qiao Wu Jiaxi Zhou Lin Liu Junjie Hu Jin-Tang Dong Zhengmao Zhu
author_facet	Ang Gao Tonghua Sun Gui Ma Jiangran Cao Qingxia Hu Ling Chen Yanxin Wang Qianying Wang Jiafu Sun Rui Wu Qiao Wu Jiaxi Zhou Lin Liu Junjie Hu Jin-Tang Dong Zhengmao Zhu
author_sort	Ang Gao
title	LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
title_short	LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
title_full	LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
title_fullStr	LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
title_full_unstemmed	LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
title_sort	lem4 confers tamoxifen resistance to breast cancer cells by activating cyclin d-cdk4/6-rb and erα pathway
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/7ff9424b6d604decaed08aa4fac77058
work_keys_str_mv	AT anggao lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT tonghuasun lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT guima lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT jiangrancao lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT qingxiahu lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT lingchen lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT yanxinwang lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT qianyingwang lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT jiafusun lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT ruiwu lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT qiaowu lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT jiaxizhou lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT linliu lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT junjiehu lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT jintangdong lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway AT zhengmaozhu lem4conferstamoxifenresistancetobreastcancercellsbyactivatingcyclindcdk46rbanderapathway
_version_	1718390845297655808

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

Ejemplares similares